Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction

BMC Medicine

Victor G Vogel¹ 

[1] Director, Breast Medical Oncology/Research, Geisinger Health System, Danville 17822, PA, USA

关键词: Tamoxifen;    Selective estrogen receptor modulators;    Risk reduction;    Chemoprevention;    Breast cancer risk;    Aromatase inhibitors;   

Others  :  1145222
DOI  :  10.1186/s12916-015-0300-0

 received in 2015-02-18, accepted in 2015-02-19,  发布年份 2015

【 摘 要 】

Selective estrogen receptor modulators (SERMs) reduce the risk of recurrence of invasive breast cancer and the incidence of first breast cancers in women who are at increased risk. Multiple, randomized clinical trials have shown both the efficacy and safety of SERMs in reducing the risk of breast cancer. Long-term follow-up as long as 20 years in the randomized trials shows persistent efficacy with acceptable safety. Hormone replacement therapy given concurrently with tamoxifen abrogates its preventive effect, but women with atypical hyperplasia derive particular benefit from SERM therapy. Aromatase inhibitors also reduce the risk of developing invasive breast cancer, but the experience with them for risk reduction is limited to few trials. National organizations have made recommendations to use SERMs and aromatase inhibitors to reduce the risk of breast cancer in high-risk women and additional efforts should be made to increase their use in clinical practice, where the number of women needed to treat to prevent one case of breast cancer conforms to accepted standards of preventive medicine.

【 授权许可】

   
2015 Vogel; licensee BioMed Central.

【 参考文献 】

• [1]Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005, 97:1652-1662.
• [2]Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90:1371-1388.
• [3]Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998, 352:98-101.
• [4]Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007, 99:283-290.
• [5]Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women: Italian Tamoxifen Prevention Study. Lancet. 1998, 352:93-97.
• [6]Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al.: Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013, 381:1827-1834.
• [7]Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al.: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002, 360:817-824.
• [8]Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al.: Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007, 99:272-282.
• [9]Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al.: Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J Natl Cancer Inst. 2011, 103:744-752.
• [10]Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41 [Erratum, JAMA 2006;296:2946, 2007;298:973].
• [11]Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al.: Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res. 2010, 3:696-706.
• [12]Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91 [Erratum, N Engl J Med 2011;365:1361].
• [13]Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125–34 [Erratum, Breast Cancer Res Treat. 2001;67:191].
• [14]Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004, 96:1751-1761.
• [15]Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006, 355:125-137.
• [16]LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, et al.: Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010, 102:1706-1715.
• [17]Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al.: Tamoxifen for prevention of breast cancer: extended longterm follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015, 16:67-75.
• [18]Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, et al.: Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006, 295:1647-1657.
• [19]Vogel VG, Costantino JP, Wickerham DL, McKasskill-Stevens W, Clarfeld R, Grant MD, et al.: Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowell Project breast cancer chemoprevention trials. J Natl Cancer Inst Monographs. 2010, 2010:181-186.
• [20]Cuzick J, Sestak I, Forbes JF, Cawthorn S, Dowsett M, Knox J, et al.: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014, 383:1041-1048.
• [21]Vogel VG: Tipping the balance for the primary prevention of breast cancer. J Natl Cancer Inst. 2010, 102:1-3.
• [22]Freedman AN, Costantino JP, Gail MH, Graubard BI, Monaco A, Vogel VG, et al.: A benefit/risk assessment tool for breast cancer chemoprevention treatment. J Clin Oncol. 2011, 29:2327-2333.
• [23]Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985, 312:146-151.
• [24]Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K: Atypical hyperplasia of the breast — risk assessment and management options. N Engl J Med. 2015, 372:78-89.
• [25]Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al.: Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013, 31:2942-2962.